APA (7th ed.) Citation

Hagerman, R., Jacquemont, S., Berry-Kravis, E., Des Portes, V., Stanfield, A., Koumaras, B., . . . von Raison, F. (2018). Mavoglurant in Fragile X Syndrome: Results of two open-label, extension trials in adults and adolescents. Scientific Reports, 8(1), 1. https://doi.org/10.1038/s41598-018-34978-4

Chicago Style (17th ed.) Citation

Hagerman, Randi, et al. "Mavoglurant in Fragile X Syndrome: Results of Two Open-label, Extension Trials in Adults and Adolescents." Scientific Reports 8, no. 1 (2018): 1. https://doi.org/10.1038/s41598-018-34978-4.

MLA (9th ed.) Citation

Hagerman, Randi, et al. "Mavoglurant in Fragile X Syndrome: Results of Two Open-label, Extension Trials in Adults and Adolescents." Scientific Reports, vol. 8, no. 1, 2018, p. 1, https://doi.org/10.1038/s41598-018-34978-4.